tbuckley/cabot-search huggingface dataset:
C‐reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria
Authors: P. Kolkhir, S. Altrichter, T. Hawro, M. Maurer
Journal: Allergy (2017)

Elevated levels of C-reactive protein (CRP), a sensitive marker of inflammation, have been consistently reported in chronic spontaneous urticaria (CSU). Here, we retrospectively analyzed data from 1253 CSU patients from 2 centers to answer the following questions: (i) What is the prevalence of elevated levels of CRP in CSU? (ii) Why do CSU patients show elevated levels of CRP? (iii) Are elevated CRP levels relevant?Serum levels of CRP were measured by the nephelometric method. We collected information regarding various laboratory tests including ESR, CBC with differential, D-dimer, fibrinogen, C3, C4, IL-6, etc. For most patients, we also collected data on age, gender, duration of CSU, presence of angioedema, activity (UAS at the time of blood sampling and for 7 days), quality of life (CU-Q2oL and/or DLQI), comorbidities and possible causes of CSU, and autologous serum skin test (ASST) response. The efficacy of second-generation antihistamines was evaluated on the day of blood collecting.One-third of CSU patients had elevated levels of CRP. Higher levels of CRP were associated with ASST positivity (P = .009) and arterial hypertension (P = .005), but not with other possible causes or comorbidities of CSU. C-reactive protein correlated with urticaria activity (P < .001), quality of life impairment (P = .026), and inflammatory and coagulation markers (P < .001). C-reactive protein levels were significantly higher in nonresponders to antihistamines as compared to responders (P < .001).Elevated levels of CRP are common and relevant in CSU patients. The assessment of CRP levels may help to optimize the management of patients with CSU.
PATH-21. IDH-MUTATED, 19q DELETED, TP53 MUTATED ANAPLASTIC GLIOMAS CONSTITUTE A SUBGROUP THAT LOOK LIKE AND BEHAVE LIKE ANAPLASTIC OLIGODENDROGLIOMAS
Authors: Ryohei Otani, Takeo Uzuka, Fumi Higuchi, Hazuki Matsuda, Shota Tanaka, Akitake Mukasa, Kohichi Ichimura, Phyo Kim, Keisuke Ueki
Journal: Neuro-Oncology (2017)

Lower grade gliomas with IDH-mutation are divided into two major entities by genetic alteration pattern: astrocytomas with TP53/ATRX mutations and oligodendrogliomas with 1p/19q codeleted/TERT promotor mutations. Clinicopathological features of those two entities are different, with the latter mostly showing distinctive histological features with isomorphic round nuclei with perinuclear halo, and conferring longer survival. However, we noticed that a small subgroup of the astrocytomas demonstrate clinicopathological features similar to oligodendrogliomas. 42 IDH-mutated anaplastic diffuse gliomas were examined on molecular genetic profiles, histological features, and clinical outcome (OS). There were 23 1p/19q codeleted tumors and 19 non-codeleted tumors. Of the 19 non-codeleted tumors, 7 showed 19q deletion only, with all having TP53 mutation as well, and showed oligodendroglia-like tumor cells with occasional neuronal differentiation, the histological features commonly observed in oligodendrogliomas. Furthermore, the prognoses of those 7 tumors were better than other anaplastic astrocytomas, with medial OSs of 105 mo. vs. 44 months. Therefore, the 19q-deleted, IDH-mutated, TP53 mutated diffuse gliomas may constitute a subgroup that look like oligodendrogliomas and behave like oligodendrogliomas, albeit diagnosed as astrocytomas by the current diagnostic criteria.
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study
Authors: Mark A. Boyd, Amanda Mocroft, Lene Ryom, Antonella d’Arminio Monforte, Caroline Sabin, Wafaa M. El-Sadr, Camilla Ingrid Hatleberg, Stephane De Wit, Rainer Weber, Eric Fontas, Andrew Phillips, Fabrice Bonnet, Peter Reiss, Jens Lundgren, Matthew Law
Journal: PLoS Medicine (2017)

Background The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has developed predictive risk scores for cardiovascular disease (CVD) and chronic kidney disease (CKD, defined as confirmed estimated glomerular filtration rate [eGFR] ≤ 60 ml/min/1.73 m2) events in HIV-positive people. We hypothesized that participants in D:A:D at high (>5%) predicted risk for both CVD and CKD would be at even greater risk for CVD and CKD events. Methods and findings We included all participants with complete risk factor (covariate) data, baseline eGFR > 60 ml/min/1.73 m2, and a confirmed (>3 months apart) eGFR < 60 ml/min/1.73 m2 thereafter to calculate CVD and CKD risk scores. We calculated CVD and CKD event rates by predicted 5-year CVD and CKD risk groups (≤1%, >1%–5%, >5%) and fitted Poisson models to assess whether CVD and CKD risk group effects were multiplicative. A total of 27,215 participants contributed 202,034 person-years of follow-up: 74% male, median (IQR) age 42 (36, 49) years, median (IQR) baseline year of follow-up 2005 (2004, 2008). D:A:D risk equations predicted 3,560 (13.1%) participants at high CVD risk, 4,996 (18.4%) participants at high CKD risk, and 1,585 (5.8%) participants at both high CKD and high CVD risk. CVD and CKD event rates by predicted risk group were multiplicative. Participants at high CVD risk had a 5.63-fold (95% CI 4.47, 7.09, p < 0.001) increase in CKD events compared to those at low risk; participants at high CKD risk had a 1.31-fold (95% CI 1.09, 1.56, p = 0.005) increase in CVD events compared to those at low risk. Participants' CVD and CKD risk groups had multiplicative predictive effects, with no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively). The main study limitation is the difference in the ascertainment of the clinically defined CVD endpoints and the laboratory-defined CKD endpoints. Conclusions We found that people at high predicted risk for both CVD and CKD have substantially greater risks for both CVD and CKD events compared with those at low predicted risk for both outcomes, and compared to those at high predicted risk for only CVD or CKD events. This suggests that CVD and CKD risk in HIV-positive persons should be assessed together. The results further encourage clinicians to prioritise addressing modifiable risks for CVD and CKD in HIV-positive people.
P2.09-007 Pleural Biopsy in Patients Suspected of Malignant Pleural Mesothelioma Consecutive 377 Cases
Authors: M. Hashimoto, T. Nakamichi, A. Fukuda, A. Kuroda, T. Takuwa, S. Matsumoto, N. Kondo, T. Tsujimura, S. Hasegawa
Journal: Journal of Thoracic Oncology (2017)
The diagnostic value and histologic correlate of distinct patterns of shiny white streaks for the diagnosis of melanoma: A retrospective, case-control study
Authors: Anna Eliza Verzi, Victor L. Quan, Kara E. Walton, Mary C. Martini, Ashfaq A. Marghoob, Erin M. Garfield, Betty Y. Kong, Maria Cristina Isales, Timothy VandenBoom, Bin Zhang, Dennis P. West, Pedram Gerami
Journal: Journal of the American Academy of Dermatology (2017)
PUB003 Metastases in T1-T2 classed Lung Cancer
Authors: H. Neji, R. Ouji, M. Attia, H. Gharsalli, S. Laabidi, I. Baccouche, A. Mekkaoui, S. Hantous-Zannad, K. Ben Miled-M'Rad
Journal: Journal of Thoracic Oncology (2017)
OA 11.06 Lung Cancer Diagnosis and Assessment as a System Design Problem: Creating an Award Winning Program with Patient Advocates as Co-Designers
Authors: J. Pantarotto, M. Fung-Kee-Fung, D. Maziak, J. Smylie, L. Taylor, T. Timlin, T. Cacciotti, P. Villeneuve, C. Dennie, C. Bornais, J. Aquino, P. Wheatley-Price, R. Ozer, D. Stewart
Journal: Journal of Thoracic Oncology (2017)
P1.05-001 Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non-Small Cell Lung Cancer
Authors: G. Huang, X. Ye, X. Yang, A. Zheng, W. Li, J. Wang, X. Han, Z. Wei, M. Meng, Y. Ni
Journal: Journal of Thoracic Oncology (2017)
MNGI-15. IMPACT OF RADIATION THERAPY ON SURVIVAL OF PATIENTS WITH HIGH-GRADE MENINGIOMAS
Authors: Smathorn Thakolwiboon, Pornsuk Cheunsuchon, Panatna Anekwiang, Sith Sathornsumetee
Journal: Neuro-Oncology (2017)

High-grade (WHO grade II and III) meningiomas represent a small subset of meningiomas with aggressive biology and high rate of recurrence. The mainstay treatment for high-grade meningiomas is surgery whereas the role of adjuvant radiotherapy (RT) remains controversial. We retrospectively evaluated the impact of RT following resection on survival of 65 patients with high-grade meningiomas at our institution between 2006 and 2010. Of 65 patients, 44 (68%) were female. The median age of diagnosis was 51.3 years. Of 46 patients who underwent gross total resection (GTR), 16 (34.8%) patients received RT, whereas 14 (73.7%) of 19 patients who underwent subtotal resection (STR) received RT. At a median follow up 66.6 months, the 5-year OS and 5-year PFS rates for all 65 patients were 65.4% and 53.6%, respectively. Postoperative RT did not improve OS or PFS in unselected high-grade meningiomas. However, adjuvant RT following STR significantly improved PFS compared with STR alone (P = 0.018) with the 5-year PFS rates with and without adjuvant RT of 71% and 40%, respectively. The 5-year OS rates for STR patients with and without RT were 86% and 40%, respectively. In the GTR group, adjuvant RT was not associated with significant survival benefits. In conclusion, adjuvant RT after STR for high-grade meningiomas improved local disease control and survival compared with STR alone.
P1.16-018 Intraoperative Detection of Tumor Resection Margin via Inhalation of Fluorescent Imaging Agents
Authors: Y.H. Quan, J. Lim, B.H. Choi, J. Rho, R. Xu, Y. Choi, Y.H. Choi, J. Park, H. Kim
Journal: Journal of Thoracic Oncology (2017)
P2.02-057 Expression of MGAT4a and MGAT5 Are Correlated with Poorer Outcome in Advanced Lung Adenocarcinoma
Authors: Y. Nakanishi, H. Nishimaki, I. Tsujino, N. Takahashi, M. Shimamura, H. Kobayashi, X.Y. Tang, Y. Kusumi, S. Hashimoto, S. Masuda
Journal: Journal of Thoracic Oncology (2017)
P1.01-045 Companion Diagnostic Tests for EGFR, ALK and ROS-1 vs NGS in Advanced NSCLC Patients - Which Is the Best in Terms of Cost and Effective?
Authors: L. Schluckebier, R. Caetano, V. Aran, O. Garay, C.G. Ferreira
Journal: Journal of Thoracic Oncology (2017)
QLIF-36. ROLE OF NURSES FOR THE IMPLEMENTATION OF TTFIELDS IN DAILY CLINICAL ROUTINE IN GLIOBLASTOMA TREATMENT
Authors: Mandy Kilias, Cristina Pellet
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is the most common type of primary malignant brain tumor in adults and the diagnosis is devastating to patients and their families. Treatment includes many modalities such as surgery, radiation, chemotherapy and tumor treating fields (TTFields). The latter is a new therapy involves placing transducer arrays that emit alternating electric fields on the shaved scalp to interfere with tumor cell division. Personalizing best treatment decision to achieve optimal therapy efficacy requires profound and extensive patient education. In this context, it is of critical value to have oncology nurses as an integral part of the therapy algorithm. To implement TTFields into GBM therapy we critically analyzed our current treatment pathway to find out where nurses can improve interactions with GBM patients. In addition, we performed a quality assessment of specific wording used to explain TTFields to the patients to guide them through TTFields therapy. Specific training of nurses to educate patients on how to integrate TTFields therapy into their daily work-life increases therapy acceptance and compliance. We successfully assessed how nurses can integrate patient education into the treatment pathway. Starting at diagnosis and further on during radiochemotherapy, we present all treatment options including TTFields repeatedly in a patient adapted way. This allows patients to make conscious treatment decisions that ensure acceptance and compliance. In addition the integration of nurses in the treatment team reduced the physicians’ daily work load. Specific TTFields training for nurses fundamentally shaped the understanding of the therapy and subsequently improved patient education, acceptance and compliance. This procedure reduces physician’s work load, increases motivation of nurses and improves therapy efficacy to deliver the best treatment to patients with GBM. We experienced benefits and therefore suggest implementing trained nurses into the GBM therapy algorithm.
Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma
Authors: David G. Mummy, Stanley J. Kruger, Wei Zha, Ronald L. Sorkness, Nizar N. Jarjour, Mark L. Schiebler, Loren C. Denlinger, Michael D. Evans, Sean B. Fain
Journal: Journal of Allergy and Clinical Immunology (2017)
RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration
Authors: Daisuke Ito, Mami Hatano, Norihiro Suzuki
Journal: Science Translational Medicine (2017)

Advanced genetic approaches have accelerated the identification of causative genes linked to the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Most of the disease-related proteins encoded by these genes form aggregates in the cellular machineries that regulate RNA and protein quality control in cells. Cross-talk among the signaling pathways governing these machineries leads to pathological cascades mediated by the accumulation of mutant RNA binding proteins. We outline the molecular basis of ALS and FTD pathogenesis and discuss the prospects for therapeutic strategies to treat these diseases.
PATH-15. OPTICAL ANALYSIS OF HUMAN BRAIN TUMORS BY RAMAN SPECTROSCOPY
Authors: Ortud Uckermann, Robert Galli, Matthias Meinhardt, Gerald Steiner, Gabriele Schackert, Matthias Kirsch
Journal: Neuro-Oncology (2017)

Raman spectroscopy (RS)reveals the molecular composition of tissues and proved to be suitable for intraoperative in situ diagnosis of glioma, including IDH1 genotype. We aimed to investigate fresh tissue biopsies to approximate the the potential and limitations of intraoperative Raman spectroscopy. 208 biopsies were obtained during brain tumor surgery and without any further processing analyzed by RS. Samples from epilepsy surgery served as nontumor control tissues. Spectra were obtained with a RamanRxn1T (Kaiser Optical Systems Inc) coupled to a microscope at five positions of each sample. Data analysis was performed using MATLAB and statistical analysis using Fisher’s coefficient. RS of 51 meningioma, 53 primary GBM, 19 recurrent GBM, 11 astrocytoma, 8 oligodendroglioma, 6 oligoastrocytoma, 8 neurinoma, 24 metastases, and 16 other tumors were acquired. Furthermore, three samples of necrotic tissue and nine nontumor human brain tissue were analyzed. Raman bands related to hemoglobin (754 cm-1 and 1540-1570 cm-1) reliably detected contamination with blood. Moreover, an band at 959 cm-1 indicated PO4-groups of calcium hydroxyapatite. All tumor types showed a significant reduction in the spectral range 1050-1150 cm-1 compared to non-tumor brain tissue according to the Fisher’s coefficient. In GBM, bands related to lipids (1297, 2850, 3011 cm-1) were strongly reduced, teh protein band at 1660 cm-1 was increased. Neurinoma exhibited additional peaks at 1158 and 1521 cm-1 which are assigned to carotinoids. Cholesterol at 700 cm-1 was largely missing in brain metastases, whereas collagen related signals were increased. Raman spectra of meningioma were characterized by higher intensities of bands assigned to (phospho)lipids and DNA compared to dura. The RS of fresh biopsies measured wthin the OR were in accordance to previous data from tissue sections. Perspectively, this provides a concept for in situ tissue classification to assist neuropathologists and neurosurgeons for intraoperative - integrated diagnosis.
Annals Story Slam - A Missed Opportunity
Authors: Carrie A. Horwitch
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 November 2017Annals Story Slam - A Missed OpportunityFREECarrie A. Horwitch, MD, MPHCarrie A. Horwitch, MD, MPHVirginia Mason Medical Center, Seattle, Washington (C.A.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0064 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - A Missed Opportunity "A Missed Opportunity," by Dr. Carrie A. Horwitch (Duration 3:40)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video. Here, Dr. Horwitch relays her story of balancing doctoring and parenting.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Virginia Mason Medical Center, Seattle, Washington (C.A.H.)Current Author Address: Carrie A. Horwitch, MD, MPH, Virginia Mason Medical Center, 1100 Ninth Avenue, C8-GIM, Seattle, WA 98101; e-mail, carrie.[email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 November 2017Volume 167, Issue 9Page: SS1 ePublished: 7 November 2017 Issue Published: 7 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Réseau Européen de Surveillance Sérologique
Authors: K Osborne, J Weinberg, E Miller
Journal: Eurosurveillance (1997)

L'objectif de la surveillance serologique est de controler le degre d'immunite d'une population vis-a-vis de certaines maladies afin d'ameliorer la qualite des informations sur lesquelles sont basees les mesures de sante publique comme les programmes de vaccination. En Angleterre et au Pays de Galles, une surveillance serologique a ete mise en place en 1987 pour controler les effets d'un nouveau programme de vaccination contre la rougeole, les oreillons et la rubeole (ROR) (1). L'identification d'un accroissement de la proportion d'enfants d'âge scolaire susceptibles a la rougeole montra l'interet de cette surveillance. A partir de cette observation, des techniques de modelisation mathematique permirent de predire une epidemie importante de rougeole chez ces enfants (2). Ces previsions etaient renforcees par des arguments epidemiologiques provenant d'autres sources. En consequence, une campagne de vaccination nationale pour proteger ces enfants fut menee en 1994 (3).
TMIC-19. ASTROCYTIC S1P3 SIGNALING MODULATES BLOOD-TUMOR BARRIER PERMEABILITY IN BRAIN METASTASES
Authors: Brunilde Gril, Anurag N Paranjape, Stephan Woditschka, Jeffrey Hanson, Xiaolin Wu, Renata Duchnowska, Priscilla K Brastianos, Cody Peer, William D Figg, Gary T Pauly, Joel P Schneider, Patricia Steeg
Journal: Neuro-Oncology (2017)

Breast cancer brain metastases are incurable. The blood-brain barrier (BBB) is a multicellular dynamic structure regulating exchanges between the blood and the central nervous system. As cancer cells colonize the brain, the BBB evolves into a blood-tumor barrier (BTB) and remains a potent barrier to compound penetration, contributing to poor efficacy of CNS chemotherapy. Identifying the molecular underpinnings of BBB/BTB permeability will lead to the development of efficacious treatments. Three mouse models of brain metastasis of breast cancer (BMBC) were developed: a triple negative (231-BR) and two HER2 overexpressing (SUM190-BR, JIMT-1-BR) subtypes. Paracellular permeability of the BTB was assessed using 3kDa Texas Red dextran (TRD). Combining fluorescent imaging techniques with laser capture microdissection, highly vs. poorly permeable metastatic lesions were dissected. Subsequently, gene expression profiling was performed on extracted RNA. Only 10% of the metastatic lesions harbored a TRD diffusion correlating with chemotherapy efficacy (i.e. highly permeable lesions). Several genes were differentially expressed between highly and poorly permeable metastases. S1PR3, sphingosine-1-phosphate receptor 3, showed a 2.4-fold increase (P=0.02) in RNA expression in highly permeable lesions. We confirmed this result at a protein level using immunostaining: S1PR3 was overexpressed by neuroinflammatory astrocytes surrounding metastases in the highly permeable metastases in the three BMBC models (231-BR, P=0.034; JIMT-1-BR, P=0.010 and SUM190-BR, P=0.0162). S1P3+ astrocytes were detected in human craniotomies of brain metastases, validating the clinical relevance of our findings. To investigate the functional role of S1PR3 in BTB permeability, mice were treated with an S1P3 antagonist for four days at 10mg/kg twice a day. S1P3 antagonist significantly decreased the diffusion of TRD by 3-fold (P=0.0118). This study represents an important proof of concept for the modulation of BTB permeability through reactive astrocytes. These data may identify new strategies to selectively permeabilize the BTB and enhance chemotherapeutic efficacy.
PDCT-23. PROLIFERATION INDEX INFLUENCES INITIAL RESPONSE PATTERN OF PEDIATRIC HIGH-GRADE GLIOMAS TREATED WITH HSV-1 G207 ONCOLYTIC VIROTHERAPY
Authors: Asim Bag, Rong Li, Yancey Gillespie, James Markert, James Johnston, Gregory K Friedman
Journal: Neuro-Oncology (2017)

Genetically engineered oncolytic HSV-1 G207, which lacks genes essential for replication in normal brain, is currently being studied in a first-in-human children clinical trial of intratumoral virus inoculation in recurrent or progressive supratentorial malignant tumors. We describe the initial pattern of response of patients treated at the first dose level (107 plaque-forming units). Patients underwent a biopsy to confirm viable tumor and then had up to four silastic catheters placed into enhancing areas of tumor. The following day, G207 was infused over 6 hours. Patients had an MRI prior to therapy, 3 days after therapy, and at day 28-36 post-G207. Immunohistochemistry was performed on biopsy specimens and MIB-1% was calculated. Four high-grade gliomas (3 glioblastoma and 1 anaplastic astrocytoma) in three subjects were treated; one subject had multifocal disease with two foci treated. Two tumors had a high proliferation index (up to 70%) and two had a low proliferation index (≤5%). Other than the changes related to catheter placement, no additional changes were noted on the day 3 MRI. The initial response at day 28-36 of the highly proliferative tumors included: 1) development of a necrotic center with enlargement of enhancing component; 2) worsening of peritumoral T2 abnormal areas; 3) new foci of intratumoral micro-hemorrhage; 4) increased mean apparent diffusion coefficient (mADC); 5) lowered mean relative cerebral blood volume (rCBV); and 6) increased T2 relaxation time with a clear gradient of these changes based on the distance from the catheter tip (maximum change closest to the catheter tip and no change farthest away). These MRI changes likely suggest pseudoprogression. Except for mild increase in the mADC, tumors with low proliferation index demonstrated no significant changes from the pretreatment MRI. This data suggests that the proliferation index may affect the pattern of response in pediatric high-grade gliomas treated with oncolytic HSV-1.
P2.03-003 Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor
Authors: T. Hsia, C. Tu, H. Chen, S. Chen, C. Chen, W. Liao, C. Li, C. Lin, C. Li, C. Chien
Journal: Journal of Thoracic Oncology (2017)